New Data in NSCLC Bolster Support for Perioperative Immunotherapy
(MedPage Today) -- CHICAGO -- A randomized trial testing the addition of perioperative pembrolizumab (Keytruda) to chemotherapy in operable non-small cell lung cancer (NSCLC) hit one of its two primary endpoints in an interim analysis, with a...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer